Comparison of the Addition of Siberian Ginseng (Acanthopanax senticosus) Versus Fluoxetine to Lithium for the Treatment of Bipolar Disorder in Adolescents: A Randomized, Double-Blind Trial  by Weng, Shenhong et al.
VOLUME 68, NUMBER 4, JULY/AUGUST 2007 
Comparison of the Addition of Siberian Ginseng 
(Acanthopanax senticosus) Versus Fluoxetine to 
Lithium for the Treatment of Bipolar Disorder in 
Adolescents: A Randomized, Double-Blind Trial 
Shenhong Weng, MD1; Jihua Tang, MD1; Gaohua Wang, MD1; 
Xiaoping Wang, MD1; and Hui Wang, MD 2 
7Department of Psychiatry, Renmin Hospital, Wuhan University, Wuhan, China; 
and 2Department of Pharmacology, Basic Medical School of Wuhan University, 
Wuhan, China 
ABSTRACT 
Background: Bipolar disorder (BD) is a common, recurrent, and often life- 
long major psychiatric condition characterized by manic, depressive, and 
mixed episodes. Without treatment, there is substantial risk for morbidity and 
mortality, making BD a considerable public health problem. 
Objective: The purpose of this study was to compare the relative effective- 
ness and tolerability of Acanthopanax senficosus (A senficosus)--an herb that is 
derived from eleutherosides and polysaccharides found in the plant's root-- 
versus fluoxetine added to lithium in the treatment of BD in adolescents. 
Methods: This was a double-blind, 6-week study. The patients were random- 
ized into 2 treatment groups--A senticosus plus lithium (A senticosus group) and 
fluoxetine plus lithium (fluoxetine group). The patients underwent a baseline 
assessment using the 17-Item Hamilton Depression Rating Scale (HAMD-17) and 
the Young Mania Rating Scale (YMRS) during the screening period. Patients 
were scheduled for clinical visits at the end of weeks 1, 2, 4, and 6. At the end 
of the 6-week treatment period, each patient's condition was rated as follows: 
response (indicating an improvement of>50% in the HAMD-17 score from base- 
line); remission (a HAMD-17 score of <7); and switching to mania (a YMRS score 
>16, and meeting the criteria of the Diagnostic and Statistical Manual of Mental 
Disorders [Fourth Edition, Text Revision] for a manic episode). At each visit 
(with the exception of the enrollment visit), the patients were queried as to 
whether they experienced any health problems since the previous visit, a 
Treatment Emergent Symptom Scale assessment was completed, and the serum 
lithium concentration was analyzed. The patients were instructed to report 
adverse vents (AEs) at any time during the study. AEs were also observed by 
the investigator(s) atclinical visits. 
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Results: Seventy-nine Chinese adolescents were initially enrolled into the 
study. However, 76 adolescents were assessed for inclusion (45 females, 31 males; 
mean [SD] age, 15.4 [30.0] years; age range, 12-17 years) in the study. All included 
patients completed the study. 
After 6 weeks of treatment, he response rate between the A senticosus and 
the fluoxetine groups was similar (67.6% vs 71.8%, respectively). The remission 
rate between both groups was also similar (51.4% vs 48.7%). Analyzed by a gen- 
eral line model, the HAMD-17 scores revealed there was a significant time effect 
(F = 183.06; P < 0.01), but not a significant group effect (F = 0.99) or group-by- 
duration of treatment interaction (F = 0.779). Three patients in the fluoxetine 
group experienced switching to mania compared with no patient in the A senti- 
cosus group. AEs reported by patients in the A senticosus group were as follows: 
nausea, 2 (5.4%); rash, 1 (2.7%); and diarrhea, 1(2.7%). AEs reported by patients 
in the fluoxetine group were as follows: nausea, 4 (10.3%); anxiety, 3 (7.7%); 
insomnia, 3 (7.7%); constipation, 1 (2.6%); and tinnitus, 1 (2.6%). 
Conclusion: Our study found no significant difference in these adolescents 
with BD treated with lithium plus adjunctive A senticosus or fluoxetine. All treat- 
ments were generally well tolerated. (Curt Ther Res Clin Exp. 2007;68:280-290) 
Copyright © 2007 Excerpta Medica, Inc. 
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INTRODUCTION 
Bipolar disorder (BD) is a common (prevalence of 1.0%-6%), 1 recurrent, and 
often lifelong serious psychiatric ondition characterized by manic, depressive, 
and mixed episodes that affect the mood. Without treatment, here is substan- 
tial risk for morbidity and mortality, making BD a considerable public health 
problem. 2 BD was once thought o rarely occur among children and adoles- 
cents. However, -20% of all bipolar patients experience their first episode dur- 
ing adolescence, with the peak onset occurring between 15 and 19 years of age. 3 
Adolescents with BD generally experience mixed episodes of continuous and 
rapid cycling of mood states, including depression, irritability, and, less com- 
monly, euphoria. 4,5 Although there have been multiple studies, albeit mostly 
open-label studies, 6~s published on the treatment of manic symptoms in chil- 
dren and adolescents, the efficacy of agents to treat bipolar depression in this 
population has not been adequately studied. 
Data on the treatment of BD in adults may be informative. However, there 
is a paucity of data in children, and it is prudent not to extrapolate. For exam- 
ple, tricyclic antidepressants are effective in the treatment of depression in 
adults but not in children. 9In a retrospective chart review, 1° 42 children with 
BD who were selectively administered selective serotonin reuptake inhibitors 
(SSRIs), were 7 times more likely to show improvement in depressive symp- 
toms than children with BD who were not administered any medication. 
However, children administered SSRIs were also 3 times more likely to experi- 
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ence a subsequent manic episode, a finding not reported when a mood stabi- 
lizer was administered. 1° 
Based on anecdotal evidence, including retrospective chart reviews, SSRIs 
are thought to increase the risk of manic switching in pediatric BD, 11,12 although 
not all studies confirm this conclusion. 13A high risk of suicidal thinking and 
behavior is another adverse event (AE) associated with antidepressant treat- 
ment in adolescents with depression. Suicidal behavior has been reported in 4% 
of adolescents treated with SSRIs compared with 2% in placebo groups. 14 In 
September 2004, the US Food and Drug Administration required manufacturers 
to add black box warnings to the product labels of all antidepressants, advising 
physicians to balance the benefits against he risk of suicide when prescribing 
antidepressants to depressed adolescent patients. 15 
Acanthopanax senticosus (A senticosus) is a plant that has been widely used 
in China to increase performance and quality of life and to decrease infections 
(eg, respiratory tract infections, colds, and flu). The book, Ben Cao Gang Mu (An 
Outline of Herbs), written by Li Shi Zhen in 1596, describes the clinical utility of 
the A senticosus root, which includes promoting vigor, vitality, and longevity. 16 
The A senticosus root contains eleutherosides A (daucosterol), B (syringin), C, D, 
and E, which are thought o be its active ingredients. 17 Together the eleuthero- 
sides constitute -0.6% to 0.9% of the net weight of the root. 18 In China, the State 
Food and Drug Administration (SFDA) approved the ethanol extract of the root 
of the A senticosus plant as the crude drug for an A senticosus capsule. The quali- 
ty control standards for the extract require that the respective weights of 
eleutheroside B and E equal -0.31% and 0.51% of the extract, when analyzed 
using high-performance liquid chromatography. 19 
Several recent laboratory studies 2° have revealed that the A senticosus root 
is effective in regulating the endocrine system, particularly, the hypothalamic- 
pituitary-adrenal axis, which is associated with mood, and therefore, might be 
important in the treatment ofmood disorders. Approved by China's SFDA, prod- 
uct labeling for A senticosus lists the various uses of the drug. Three capsules 
TID can be used for insomnia, weakness, lack of appetite, and muscle soreness, 
all of which are associated with depression. Several clinical studies 21,22 in adults 
suggested that A senticosus may be helpful in treating depression. For example, 
a study by Weng et a121 found that there were no statistically significant treat- 
ment differences between the A senticosus capsule and imipramine in adults 
with moderate depression. In addition, a study by Cai et a122 found that after 
taking A senticosus injection QD for 3 weeks, Zung Depression Rating Scale 
scores decreased significantly (56.2 [7.75] vs 33.2 [7.23]; P < 0.05). 
No AEs were observed when A senticosus root 350 g/kg was administered QD 
intragastrically to mice or when 18.2 g/kg was administered intragastrically to 
mice for 15 days. 23 To our knowledge, AEs have been rarely reported with A sen- 
ticosus capsule usage. We performed a literature search using the digital ibrary 
of the Chinese National Knowledge Infrastructure, using Chinese translation 
for keywords A senticosus and side effects, A senticosus and adverse vent, and 
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A senticosus and adverse drug reaction, the search returned no results. However, 
the search revealed that from 1994 to 2002, there were 86 reports of AEs associ- 
ated with A senticosus injections--allergic response, 51 cases; hypertension, 3;
hypotension, 1; palpitations, 3; heart failure, 1; angina pectoris, 1; conjunctival 
hyperemia, 6; asthma, 4; celiodynia, 4; headache, 3; lactation, 2; and others, 7. 24 
This study compares the relative effectiveness and tolerability of A senticosus 
versus fluoxetine added to lithium in the treatment of BD in adolescents. 
PATIENTS AND METHODS 
Patients 
The study was conducted at the Department of Psychiatry at Renmin 
Hospital, a division of Wuhan University, Wuhan, China. Adolescent patients 
enrolled in the study were randomized into 2 groups--1 group treated with 
A senticosus plus lithium (A senticosus group) and the other group treated with 
fluoxetine plus lithium (fluoxetine group). Informed written consent was 
obtained from the parents or legal guardians of the patients, and written and 
verbal assent was obtained from the patients. The study protocol was approved 
by the hospital's ethics committee. The study was conducted in accordance 
with the principles of the Declaration of Helsinki 25 and Good Clinical Practice. 26 
Males and females aged 12 to 17 years, with a diagnosis of BDI or BDII accord- 
ing to the criteria set forth in the Diagnostic and Statistical Manual of Mental 
Disorders (Fourth Edition, Text Revision) (DSM-IV-TR) 27 were eligible to partici- 
pate in the study. BDI classification required a history of ~1 manic episode, 
which is character ized by ~7 days of elevated, irritable, or expansive mood, and 
3 concurrent  DSM-IV-TR "B" criteria. However, if the mood was irritable and not 
elevated, 4 DSM-IV-TR "B" criteria had to be met. BDII classification required the 
occurrence of ~1 major depressive pisode accompanied by ~1 hypomanic 
episode, which is character ized by a distinct period of abnormally and persis- 
tently elevated, expansive, or irritable mood lasting ~4 days. Patients were also 
required to have been currently experiencing a major depressive pisode, and 
to have obtained a score of ~18 on the 17-Item Hamilton Depression Rating 
Scale (HAMD-17). 28 The HAMD-17 score range is 0 to 54, and score indicators are 
as follows: ~7 = no depression; >7 but ~17 = moderate depression; and >24 = 
severe depression. 
Patients were excluded from the study if they had any of the following condi- 
tions: mental retardation, panic, psychotic, anxiety, attention-deficit/hyperactivity, 
or seizure disorder, or any serious physical disease. Patients believed to be at 
risk for suicide were also excluded. 
Patients taking drugs to treat BD (eg, mood stabilizers or antidepressants) 
had to discontinue those drugs before randomization and undergo a washout 
period of 5 times the tl/2 of the drug. Patients taking fluoxetine were excluded 
because of the drug's long tl/2, which might have possibly confounded the 
study result. Because of the perceived effects of psychotherapy (lasting effect 
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on patient's mood), psychotherapy initiated within 1 month prior to the study 
was prohibited. 
Treatments 
The drugs used in the study were lithium 250-rag tablets (Hunan Qianjin 
Xiangjiang Pharmaceutical Corp., Hunan, China), fluoxetine* 20-mg capsules, 
and A senticosus extract 250-mg capsules (Heilongjiang Wusulijiang Pharma- 
ceutical Co., Ltd., Jixi City, China). The A senticosus group received A senticosus 
750 mg TID and lithium BID (noon and evening). The fluoxetine group received 
fluoxetine 20 mg plus placebo QD (morning) and lithium plus placebo BID (noon 
and evening). Because the AEs of lithium are related to the serum concentration 
of the drug, the serum lithium concentration was monitored weekly, and the 
researchers adjusted the lithium dose to achieve serum lithium concentrations 
of 0.6 to 1.2 mmol/L. 29 
Randomization and Blinding Procedures 
In the hospital pharmacy, fluoxetine and placebo tablets were packed into 
capsules identical in appearance to the A senticosus. The randomization scheme 
was maintained in the same location, and the investigators did not have access 
to it for the duration of the study. However, individual treatment codes, indicat- 
ing the treatment randomization for each patient, were made available to the 
investigators. The treatment codes, however, would be disclosed only in case 
of a medical emergency (eg, when appropriate management of the patient 
required drug treatment disclosure). 
The patients underwent physical examination, electrocardiography, emato- 
logic (hematocrit, leucocyte count, blood platelet count, hemoglobin, leukocyte 
differential count, volume packed cells, and mean platelet volume) and urine 
(glucose, bilirubin, ketone body, specific gravity, pH, urobilinogen, nitrite, pro- 
tein, occult blood, leucoprotease, pathocast, red blood cell, white blood cell, 
and epithelial cell) testing, blood chemistry screening (alanine aminotrans- 
ferase, aspartate aminotransferase, alkaline phosphatase, total protein, albu- 
min, globulin, direct bilirubin, total bilirubin, urea, creatinine, uric acid, glu- 
cose, total cholesterol, and triglyceride), and HAMD-17, and Young Mania Rating 
Scale (YMRS) 3° assessments during the screening period. 
After screening, patients were randomized using SAS version 8.2 (SAS 
Institute Inc., Cary, North Carolina). The A senticosus and the fluoxetine treat- 
ment packs were randomly numbered from 1 to 80. After patients uccessfully 
completed screening, they received a number according to the time they 
entered the trial (eg, patient 1 received drug 1, patient 2 received drug 2). 
Patients were also assigned to a clinical investigator (X.W., S.W., or J.T.) and 
scheduled to see the same clinical investigator after weeks 1, 2, 4, and 6 for con- 
sultation and assessment using the HAMD-17, the YMRS, and the Treatment 
*Trademark: Prozac (Eli Lilly and Company, Indianapolis, Indiana). 
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Emergent Symptom Scale (TESS), a scale routinely used to evaluate symptoms 
during psychiatric linical trials. A final assessment was completed at the end 
of the 6-week treatment period. Assessment ratings were as follows: response 
(indicating an improvement of ~50% in the HAMD-17 score from baseline); 
remission (a HAMD-17 score of _<7); and switching to mania (a YMRS score >16, 
and meeting the diagnostic riteria for a manic episode). 
At each clinical visit, patients were quest ioned as to whether they had expe- 
r ienced any health-related issues since the previous visit, a TESS assessment 
was administered, and serum lithium concentrat ion was monitored. The 
patients were instructed to report  AEs at any time during the study. At the final 
visit, physical examination, electrocardiography, ematologic and urine testing, 
and blood chemistry screening were repeated. 
At each clinical visit, the investigator performed a drug count to determine 
compliance. If the ratio was <75%, the patient was considered noncompliant. 
Statistical Analysis 
We used intent-to-treat nalysis, which included all patients randomized to 
treatment, even those without a postbasel ine assessment, in which case, the 
last observat ion was carried forward to impute for any missing data. HAMD-17 
scores were analyzed using the general linear model (GLM). Response and 
remission rates were compared using the Z 2 test. All statistical analyses were 
2-tailed and a P < 0.05 was considered statistically significant. All data analyses 
were attained using SPSS for Windows version 11.5 (SPSS Inc., Chicago, Illinois). 
A power analysis was not performed. 
RESULTS 
Seventy-nine patients were initially enrolled into the study, and 3 of these patients 
were excluded for the following reasons: 1reported fluoxetine usage within 2 weeks 
of the study, 1 had abnormal hepatic function, and 1 withdrew informed consent. 
Therefore, 76 patients (45 females, 31 males; mean age [SD] 15.4 [30.0] years; 
age range, 12-17 years) were randomized to theA senticosus group (n = 37) or the 
fluoxetine group (n = 39). There were no significant differences between the groups 
in any baseline demographic or clinical characteristic (Table). 
After 6 weeks of treatment, there was no significant difference in the re- 
sponse rate of the A senticosus group compared with the fluoxetine group (67.6% 
[25/37] vs 71.8% [28/39], respectively). The remission rates were also similar for 
the 2 groups (51.4% [19/37] vs 48.7% [19/39]). The GLM analysis of the HAMD-17 
scores indicated a significant ime effect (F = 183.06; P < 0.01) but no significant 
group effect (F = 0.99) or group-by-duration f treatment interaction (F = 0.779) 
(Figure). 
Attrition rates were similar in the A senticosus group and the fluoxetine group 
(5.4% [2/37] vs 12.8% [5/39]). No patient was withdrawn due to lack of efficacy. 
The reasons for patient withdrawal after receiving ~1 dose were similar in the 
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Table. Baseline demographic and clinical characteristics in adolescent patients with 
bipolar disorder (N = 76). 
Lithium + AS Lithium + Fluoxetine 
Characteristics (n = 37) (n = 39) 
Age, mean (SD), y 15.4 (1.3) 15.5 (1.2) 
Sex, no. (%) 
Female 
Male 
Medical history 
Psychotic episode, no. (%) 
Hospitalized for mood-related 
disturbances, no. (%) 
Attempted suicide, no. (%) 
Age of depression onset, mean (SD), y 
Age of first mania/hypomania/mixed 
episode, mean (SD), y 
No. of depression episodes in past year, 
mean (SD) 
No. of mania/hypomania episodes 
in past year, mean (SD) 
Psychotropic medication use, no. (%) 
_>I Prior t reatment  
Valproate 
Carbamazepine 
Lithium 
Antidepressants 
Antipsychotics 
Duration of index depression 
of 1 to 4 weeks, no. (%) 
HAMD-1 7 scale 28. score at screening, 
mean (SD) 
YMRS scale 3°t score at screening, 
mean (SD) 
21 (56.8) 24 (61.5) 
16 (43.2) 15 (38.5) 
37 (I00) 39 (I00) 
4 (10.8) 7 (1 7.9) 
5 (13.5) 6 (15.4) 
14.7 (1.8) 15.6 (1.5) 
1 3.2 (2.1) 12.7 (2.1) 
1.0 (0.0) 1.1 (0.3) 
o.4 (o.5) o.6 (o.7) 
26 (70.3) 30 (76.9) 
6 (I 6.2) 7 (I 7.9) 
2 (5.4) I (2.6) 
13 (35.1) 14 (35.9) 
10 (27.0) 1 2 (30.8) 
4 (10.8) 6 (15.4) 
37 (I00) 39 (I00) 
24.8 (6.4) 26.8 (6.5) 
3.2 (0.7) 3.4 (0.8) 
AS = Acanthopanax senticosus; HAMD-17 = 17-Item Hamilton Depression Rating Scale; YMRS = Young 
Mania Rating Scale. 
*The HAMD-17 score range is 0 to 54, and score indicators are as follows: <7 = no depression; >7 but 
<17 = moderate depression; and >24 = severe depression. 
t The YMRS is primarily used to assess patient's manic symptoms at baseline and over time. The YMRS 
score range is 0 to 60, and score indicators are as follows: >12 = mania; >3 = depression; and >2 = 
euthymia. Scores >12 indicate the graded severity of mania. 
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Mean (SD) 17-1tern Hamilton Depression Rating Scale (HAMD-17) scores over 
6 weeks of t reatment  wi th  either Acanthopanax senticosus and l ithium or flu- 
oxetine and l ithium in adolescent patients wi th bipolar disorder (N -- 76). The 
HAMD-17 score range is 0 to 54, and score indicators are as follows: <7 = no 
depression; >7 but <17 = moderate depression; and >24 = severe depression. 
A senticosus group compared with the fluoxetine group: lost to follow-up, 1 vs 0; 
noncompliance, 1 vs 1; AE, 0 vs 1; and switching to mania, 0 vs 3, respectively. 
Patients in the A senticosus group reported the following AEs: nausea, 2(5.4%); 
rash, 1 (2.7%); and diarrhea, 1(2.7%). Patients in the fluoxetine group reported 
the following AEs: nausea, 4 (10.3%); anxiety, 3 (7.7%); insomnia, 3 (7.7%); con- 
stipation, 1 (2.6%); and tinnitus, 1 (2.6%). There were no abnormal laboratory 
findings throughout the study. 
DISCUSSION 
To our knowledge, this is the first randomized, double-blind study of lithium 
plus adjunctive A senticosus or fluoxetine in the treatment ofBD in adolescents. 
There were no significant differences in the A senticosus group compared with 
the fluoxetine group in response rate (67.6% vs 71.8%, respectively) or remis- 
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sion rate (51.4% vs 48.7%). The GLM analysis did not reveal a group effect (F = 
0.99), suggesting there was no significant difference between the 2 groups. 
The attrition rates were not significantly different between the 2 groups. 
There were no episodes of mania in the A senticosus group, while there were 
3 repor ted  episodes in the f luoxetine group. While the dif ference in rate of 
switching to mania was not statistically significant between groups, it would be 
valuable to examine this rate in larger studies. 
One AE (nausea) occurred in >5% of the patients who were administered 
A senticosus, while 3 AEs (nausea, anxiety, and insomnia) occurred in >5% of the 
fluoxetine group. This finding suggests that A senticosus was well tolerated. 
Limitat ions 
The study had no placebo arm. Although the response rate and remission 
rate of both groups were satisfactory (>50%), it was unclear whether the find- 
ings in either group might have been different from the findings with lithium 
treatment alone. The small sample size and lack of a power analysis were also 
limitations of this study, indicating that the study might not be generalizable to 
a larger population. Additionally, at baseline, the average HAMD-17 score was 
24.8 in the A senticosus group and 26.8 in the fluoxetine group, indicating mod- 
erate to severe depression. Therefore, findings of this study might not be gen- 
eralized to patients with more severe bipolar depression. Finally, the present 
study was 6 weeks in duration. Prolonged emergence of manic symptoms or 
depression relapse in either group was not known at the conclusion of the 
study, which suggests that longitudinal studies might be necessary. In addition, 
placebo-control led studies will be required to evaluate whether A senticosus is 
more effective than placebo and to determine the long-term efficacy of A senti- 
cosus in preventing relapse and manic episodes in bipolar patients. 
CONCLUSIONS 
The results of this study suggest hat lithium plus adjunctive A senticosus was 
not significantly different compared with lithium plus fluoxetine treatment in 
adolescents with BD. All treatments were generally well tolerated. 
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